September 2026: Charlie’s Holdings Shifts Focus to Age-Gated Flavored Vapes Amid Improving US Regulatory Landscape
Charlie’s Holdings announced a major strategic pivot toward launching America’s first age-gated, flavored disposable vapes, pointing to favorable federal court rulings and new FDA enforcement frameworks that are reshaping the U.S. nicotine market. In a letter to shareholders, the company outlined how recent regulatory shifts have significantly improved prospects for the company’s regulatory assets.
After selling 16 PMTA Products in 2025 for up to $11.7 million, Charlie’s retains 678 PMTA assets. The portfolio includes 170 4mL disposables, 170 8mL disposables, 154 12mL disposables and 184 e-liquid applications. At least 200 of these products remain active in Filing Review without MDOs. Further, 30 of Charlie’s PMTA products have been selected by the FDA for inclusion on a proposed public-facing webpage that identifies products for which the FDA generally does not intend to prioritize enforcement of PMTA requirements. All other Charlie’s products that received MDOs from the FDA were granted administrative stays by the U.S. Court of Appeals for the Fifth Circuit.
The company highlighted two primary regulatory developments that have altered the environment for flavored electronic nicotine delivery systems. First, in May 2026, the FDA granted marketing orders for Glas Inc.’s age-gated flavored pods, establishing age verification technology as a legitimate pathway for legal sales, followed in August by authorization for the JUUL2 device incorporating similar youth access restrictions. Second, on August 19, 2026, the Fifth Circuit ruled in NicQuid v. FDA to vacate a flavored marketing denial order, finding that the FDA applied its comparative-efficacy denial standard unlawfully without required notice-and-comment rulemaking procedures.
To capitalize on these shifts, Charlie’s is shifting its near-term operational priorities from traditional product lines to a test pilot of its PACHA age-gated flavored disposable vapes. Tens of thousands of finished units have arrived at the company’s warehouse, and test-market purchase commitments have been secured with a leading U.S. vapor retailer. Shipments will begin once final testing of the required consumer app is completed by software developer IKE. Additionally, the company is actively pursuing strategic partnerships and transactions with major global tobacco firms to monetize Charlie’s extensive PMTA portfolio.
August 2026: Charlie’s Holdings Reports 116% Revenue Growth, FDA Non-Enforcement Inclusion for 30 SKUs, and Key Commercial Initiatives
For the second quarter ended June 30, 2026, Charlie’s Holdings (CHUC) reported total revenue of $3.8 million, representing a 116% increase compared to $1.8 million in Q2 2025. This top-line expansion was primarily driven by higher sales of nicotine-based products and non-nicotine alternatives, notably significant sales growth from its SBX disposable vapor line. Gross profit rose 130% year-over-year to $1.1 million, with gross margins expanding to 29.4% from 27.6% in the prior-year period. Total operating expenses reached $2.4 million, up 63% from $1.4 million in Q2 2025, yielding an operating loss of $1.2 million compared to $1.0 million in Q2 2025. As of June 30, 2026, the company held $0.5 million in cash, total assets of $12.8 million, and shareholders’ equity of $3.1 million. Insiders demonstrated confidence during the first half of 2026 by purchasing $270,000 in common stock (1,350,000 restricted shares at $0.20 per share) with no warrants or inducements.
FDA Non-Enforcement Guidelines and the 30 PACHA SKUs
A central regulatory milestone highlighted in the release was the FDA’s notification to Charlie’s on June 23, 2026. The FDA tentatively identified 30 SKUs of the company’s PACHA product line—all of which have submitted Premarket Tobacco Product Applications (PMTAs)—for inclusion on the FDA’s public-facing webpage of products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements.
Management characterized this notification as a highly promising development that strengthens the company’s market positioning. Management emphasized that while the U.S. market continues to be impacted by non-compliant, illicit foreign products, Charlie’s remains focused on strict regulatory compliance, quality product engineering, and flavor innovation. This non-enforcement recognition aligns with broader industry shifts noted by the company, including recent FDA market authorizations for non-tobacco flavored ENDS products.
Commercial Plans and Strategic Rollouts
Charlie’s outlined several core commercial growth drivers aimed at expanding market share and retail footprint:
Age-Gated Flavored Disposable Launch: The company is preparing for what management considers the single most critical initiative in Charlie’s history—the rollout of America’s first age-gated flavored disposable vape. The company plans to initiate test-marketing across hundreds of compliance-oriented retail stores, a strategic move that management believes carries substantial regulatory upside and could positioned the firm for significant long-term market capitalization growth.
State-Level Approvals & SBX Expansion: Charlie’s launched its SBX 25K Virginia Tobacco disposable line across California after obtaining California Unflavored Tobacco List (UTL) authorization for four modern disposable devices.
Next-Generation Device Introductions: The company launched its high-capacity 75K disposables featuring upgraded triple mesh coil technology, refined ergonomics, increased puff capacity, and a menu of ten distinct flavors designed for adult consumers.
